Dermazin Use In Pregnancy & Lactation

Pregnancy: There are insufficient data on the use of silver sulfadiazine in human pregnancy to assess the potential damage. Silver is absorbed to a small extent. Possible effects of silver sulfadiazine on the fetus have not been studied. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity. There is a risk of hyperbilirubinemia and kernicterus in the newborn in case of systemic use of sulfonamides just before delivery, because sulfonamides displace bilirubin from the binding sites on albumin in the blood.
Given the limited experience and the previously mentioned risks sulfadiazine silver should only be used with caution in pregnant women or women who want to conceive.
Breastfeeding: It is not known whether sulfadiazine silver is excreted into breast milk. The excretion of sulfadiazine silver in milk has not been studied in animals. However, sulfonamides are excreted in small quantities in breast milk. In premature neonates and infants with glucose-6-phosphate dehydrogenase deficiency an increased risk of hyperbilirubinemia and kernicterus must be taken into account. Otherwise it is possible to breast-feed during treatment with sulfadiazine silver.